Share-based Payment Arrangement, Expense of Humacyte, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Humacyte, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Humacyte, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,510,000, a 62% increase year-over-year.
  • Humacyte, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $9,125,000, a 56% increase year-over-year.
  • Humacyte, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,137,000, a 10% decline from 2023.
  • Humacyte, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,828,000, a 10% increase from 2022.
  • Humacyte, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,184,000, a 39% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Humacyte, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $9,125,000 $2,510,000 +$958,000 +62% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $8,167,000 $2,434,000 +$997,000 +69% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $7,170,000 $2,487,000 +$1,033,000 +71% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $6,137,000 $1,694,000 +$288,000 +20% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $5,849,000 $1,552,000 -$220,000 -12% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $6,069,000 $1,437,000 -$404,000 -22% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $6,473,000 $1,454,000 -$355,000 -20% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $6,828,000 $1,406,000 -$264,000 -16% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $7,092,000 $1,772,000 +$296,000 +20% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $6,796,000 $1,841,000 +$350,000 +23% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $6,446,000 $1,809,000 +$262,000 +17% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $6,184,000 $1,670,000 -$1,141,000 -41% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $7,325,000 $1,476,000 -$401,000 -21% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,726,000 $1,491,000 -$1,439,000 -49% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $9,165,000 $1,547,000 -$981,000 -39% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $10,146,000 $2,811,000 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
Q3 2021 $1,877,000 +$707,000 +60% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $2,930,000 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $2,528,000 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q3 2020 $1,170,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3

Humacyte, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,137,000 -$691,000 -10% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $6,828,000 +$644,000 +10% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $6,184,000 -$3,962,000 -39% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $10,146,000 +$5,452,000 +116% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
2020 $4,694,000 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.